Search
CanSino Receives Approval for Phase I/II Clinical Trials of Recombinant Trivalent Poliovirus Vaccine (Sf-RVN Cells)
1 week ago /
Read about 0 minute
Author：小编
CanSino Biologics Inc. has recently announced the receipt of a Drug Clinical Trial Approval Notice for its Recombinant Trivalent Poliovirus Vaccine (Sf-RVN Cells), granted by the National Medical Products Administration. This innovative vaccine leverages protein structure design and Virus-Like Particle (VLP) assembly technology, ensuring it contains no viral genetic material while demonstrating outstanding safety and immunogenicity profiles. Currently, the vaccine is progressing through Phase I/II clinical trials in Indonesia. CanSino affirms that following this approval, it will adhere to national drug registration regulations and requirements to further advance the clinical trial process.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
